In contrast, Eli Lilly (NYSE: LLY) and Hims & Hers Health (NYSE: HIMS) both jumped on today's news. They rose 2.7% and 7%, ...

Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese ...

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...

Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license ...

Novo Nordisk Stock Dips on Pricey Bet and Drug Risk While the move could eventually expand Novo’s GLP-1 dominance, investors weren’t sold. UBT251 is still in early clinical development, which means a ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which ...

Software giant SAP has overtaken Danish drugmaker Novo Nordisk to become Europe’s most valuable company, in the latest ...

Co., Ltd. have entered into an exclusive license agreement for UBT251 for the treatment of obesity, type 2 diabetes, and other diseases.